media – Page 587 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Berkshire Hathaway, Amazon, chase partner to create healthcare company

It’s no secret Jeff Bezos has been looking to crack healthcare. But no one expected him to pull in Warren Buffett and Jamie Dimon, too.
- Source: Digital Insurance
- 441
- January 31, 2018
Company Insight healthcare
the Mayo Clinic experience

Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and normal tissue. As such, their main toxicity is inducing immune-mediated tissue damage.
- Source: acrabstracts.org
- 500
- January 30, 2018
inhibitor malignancies Researches
Sanofi snaps up Ablynx for 3.9bn euros

Sanofi will launch public offers to acquire all shares, including ADSs, warrants and convertible bonds of Ablynx. News of the deal will no doubt come as a great disappointment to Novo Nordisk, which recently stepped up its efforts to buy Ablynx with a second offer valued at around 2.6 billion euros.
- Source: Currenthollywood
- 656
- January 30, 2018
Market Views Sanofi Ablynx
What to consider when buying used medical devices and equipment

Used medical equipment is often a smart and cost-effective way of acquiring medical device products. Everything from diagnostics to monitoring medical equipment is available online for second hand purchasing but there are a couple of things to look out for and consider when investing in these products. From first-hand experience, Drugdu.com has created a list of what to look out for and what to keep in mind.
- Source: Ddu
- 694
- January 30, 2018
Ddu College medical device
Seven medicines leap closer to EU approval

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
- Source: pharmatimes
- 1,025
- January 30, 2018
CHMP diabetes EMA haemophilia A Hemlibra polices Roche
GSK’s Shingrix Gets Positive CHMP Opinion For Prevention Of Shingles

GlaxoSmithKline plc (GSK,GSK.L) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion recommending marketing authorisation for Shingrix (RELATED: CDC backs GSK’s Shingrix over Merck & Co’s Zostavax) for the prevention of shingles, or herpes zoster, and post-herpetic neuralgia or PHN
- Source: rttnews
- 611
- January 30, 2018
Company Insight herpes zoster PHN shingles Shingrix
North Colorado Medical Center invests nearly $2 million in new robotic surgery technology

Maurice Lyons remembers when lung surgery used to require him to make a 6-10 inch incision in a patients' skin and fracture a rib. He'd take the lung out, do what needed to be done and put it back. It would take patients about a week to recover enough just to leave the hospital, Lyons said.
- Source: The Tribune
- 571
- January 30, 2018
Company Insight lung medical device medtech surgery
New nanomedicine could prevent progression of pancreatic cancer

A new study published in scientific journal Nature Communications distinguishes the reason for extended pancreatic cancer survival: an inverse correlation between a known oncogene, a gene that promotes the development of cancer, and the expression of an oncosuppressor microRNA.
- Source: Israel21c
- 576
- January 30, 2018
cancer medtech pancreatic Researches
TriNetX buffs Sanofi’s digital trials and other digital health deals

Sanofi has found yet another partner to help digitize its clinical trial processes. In a statement, TriNetX announced that it will be assisting the pharmaceutical company by using patient EHRs to optimize recruitment, streamline trial investigators’ workflows, and otherwise impact the design of investigational drug trials. Sanofi has made similar arrangements to bolster its clinical trials with Science 37 and Evidation in March and July of last year, respectively.
- Source: MobiHealthNews
- 711
- January 30, 2018
Clinical Trials Company Insight EHR Sanofi
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Novartis AG (NYSE: NVS) today announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.
- Source: Novartis
- 501
- January 29, 2018
FDA GEP-NETs Lutathera® New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.